ATE213499T1 - Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose - Google Patents

Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose

Info

Publication number: ATE213499T1
Authority: AT; Austria
Prior art keywords: peptide analogues; multiple sclerosis; substitution; treatment; myelin protein
Prior art date: 1994-11-18

Application number

AT95942842T

Other languages

English (en)

Inventor

Nicholas Ling

Paul J Conlon

Amitabh Gaur

Lawrence Steinman

Original Assignee

Neurocrine Biosciences Inc

Univ Leland Stanford Junior

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-18

Filing date

1995-11-16

Publication date

2002-03-15

1995-11-16 Application filed by Neurocrine Biosciences Inc, Univ Leland Stanford Junior filed Critical Neurocrine Biosciences Inc

2002-03-15 Application granted granted Critical

2002-03-15 Publication of ATE213499T1 publication Critical patent/ATE213499T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
201000006417 multiple sclerosis Diseases 0.000 title abstract 2
102000006386 Myelin Proteins Human genes 0.000 title 1
108010083674 Myelin Proteins Proteins 0.000 title 1
238000006467 substitution reaction Methods 0.000 title 1
101001018318 Homo sapiens Myelin basic protein Proteins 0.000 abstract 1
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 abstract 1
235000001014 amino acid Nutrition 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
102000054064 human MBP Human genes 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
235000018102 proteins Nutrition 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Rehabilitation Therapy (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT95942842T 1994-11-18 1995-11-16 Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose ATE213499T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34207894A	1994-11-18	1994-11-18
PCT/US1995/014402 WO1996016085A1 (en)	1994-11-18	1995-11-16	Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Publications (1)

Publication Number	Publication Date
ATE213499T1 true ATE213499T1 (de)	2002-03-15

Family

ID=23340234

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95942842T ATE213499T1 (de)	1994-11-18	1995-11-16	Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose

Country Status (9)

Country	Link
US (4)	US6369033B1 (de)
EP (2)	EP1172376A1 (de)
JP (1)	JPH10509714A (de)
AT (1)	ATE213499T1 (de)
AU (1)	AU721898B2 (de)
CA (1)	CA2205532A1 (de)
DE (1)	DE69525544T2 (de)
MX (1)	MX9703642A (de)
WO (1)	WO1996016085A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7090982B2 (en)	1991-10-22	2006-08-15	The Governors Of The University Of Alberta	Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US6252040B1 (en)	1991-10-22	2001-06-26	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
EP0650498B1 (de) *	1992-04-09	1998-09-09	Autoimmune, Inc.	Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
CA2203629A1 (en) *	1994-10-25	1996-05-02	Dawn Smilek	Compositions and treatment for multiple sclerosis
ATE213499T1 (de) *	1994-11-18	2002-03-15	Neurocrine Biosciences Inc	Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
US6251396B1 (en) *	1994-11-18	2001-06-26	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6379670B1 (en)	1994-11-18	2002-04-30	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US6329499B1 (en)	1994-11-18	2001-12-11	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
WO1996028470A2 (en) *	1995-03-09	1996-09-19	Neurocrine Biosciences, Inc.	Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
AU1874997A (en) *	1996-02-15	1997-09-02	Pangenetics B.V.	Molecules for the induction of immunological tolerance
US20020072493A1 (en)	1998-05-19	2002-06-13	Yeda Research And Development Co. Ltd.	Activated T cells, nervous system-specific antigens and their uses
US6541608B1 (en) *	1999-02-23	2003-04-01	Baylor College Of Medicine	T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection
US20040072222A1 (en) *	2001-03-23	2004-04-15	John Matsoukas	Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)
US7658926B2 (en) *	2001-09-14	2010-02-09	Opexa Pharmaceuticals, Inc.	Autologous T-cell vaccines materials and methods
EP2363710B1 (de) *	2002-08-08	2015-07-01	Baylor College Of Medicine	Isolierung und identifizierung von t-zellen
AU2006236294A1 (en)	2005-04-19	2006-10-26	Eli Lilly And Company	Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
PT2420833E (pt) *	2006-05-05	2015-11-24	Opexa Therapeutics	Vacina de células t
EP3521309A1 (de)	2008-12-19	2019-08-07	Biogen International Neuroscience GmbH	Menschliche anti-alpha-synuclein-antikörper
US20140348861A1 (en)	2011-05-05	2014-11-27	National Institute Of Immunology	Synthetic peptides and random copolymers for the treatment of autoimmune disorders
MX357193B (es)	2011-06-23	2018-06-29	Univ Zuerich	Moleculas de union anti-alfa sinucleina.
CN103102393B (zh) *	2013-01-30	2015-01-07	北京大学	一种多肽及其在制备抑郁症治疗药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5468481A (en) *	1988-06-23	1995-11-21	Amergen, Inc.	MHC class II-peptide conjugates useful in ameliorating autoimmunity
AU651097B2 (en) *	1990-03-02	1994-07-14	Autoimmune, Inc.	Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
US5858980A (en) *	1990-03-30	1999-01-12	Autoimmune, Inc.	Peptide fragments of myelin basic protein
EP0587735B1 (de) *	1991-05-31	2000-01-26	Connetics Corporation	T-zell rezeptorpeptide als therapeutika für immun-verwandte krankheiten
CA2053799C (en) *	1991-10-22	2002-03-12	Kenneth G. Warren	Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
EP0650498B1 (de) *	1992-04-09	1998-09-09	Autoimmune, Inc.	Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
WO1995008572A1 (en) *	1993-09-22	1995-03-30	The Board Of Trustees For The Leland Stanford Junior University	Interaction of t-cell receptors and antigen in autoimmune disease
US6329499B1 (en) *	1994-11-18	2001-12-11	Neurocrine Biosciences, Inc.	Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
ATE213499T1 (de) *	1994-11-18	2002-03-15	Neurocrine Biosciences Inc	Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose

1995
- 1995-11-16 AT AT95942842T patent/ATE213499T1/de not_active IP Right Cessation
- 1995-11-16 JP JP8516910A patent/JPH10509714A/ja not_active Ceased
- 1995-11-16 CA CA002205532A patent/CA2205532A1/en not_active Abandoned
- 1995-11-16 DE DE69525544T patent/DE69525544T2/de not_active Expired - Fee Related
- 1995-11-16 EP EP01115315A patent/EP1172376A1/de not_active Withdrawn
- 1995-11-16 EP EP95942842A patent/EP0792286B1/de not_active Expired - Lifetime
- 1995-11-16 AU AU44057/96A patent/AU721898B2/en not_active Ceased
- 1995-11-16 WO PCT/US1995/014402 patent/WO1996016085A1/en not_active Ceased
1997
- 1997-05-16 MX MX9703642A patent/MX9703642A/es not_active Application Discontinuation
- 1997-10-20 US US08/953,937 patent/US6369033B1/en not_active Expired - Fee Related
2001
- 2001-11-19 US US09/989,476 patent/US6489299B2/en not_active Expired - Fee Related
2002
- 2002-10-11 US US10/270,707 patent/US6740638B2/en not_active Expired - Fee Related
2004
- 2004-04-08 US US10/820,983 patent/US20040214775A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US6369033B1 (en)	2002-04-09
MX9703642A (es)	1998-11-29
JPH10509714A (ja)	1998-09-22
US20020058627A1 (en)	2002-05-16
US6740638B2 (en)	2004-05-25
WO1996016085A1 (en)	1996-05-30
DE69525544T2 (de)	2002-08-22
DE69525544D1 (de)	2002-03-28
US20040214775A1 (en)	2004-10-28
AU4405796A (en)	1996-06-17
EP0792286A1 (de)	1997-09-03
US6489299B2 (en)	2002-12-03
US20030114380A1 (en)	2003-06-19
EP1172376A1 (de)	2002-01-16
EP0792286B1 (de)	2002-02-20
AU721898B2 (en)	2000-07-20
CA2205532A1 (en)	1996-05-30

Legal Events

Date	Code	Title	Description
2002-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE213499T1 (de)	2002-03-15	Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
ATE266043T1 (de)	2004-05-15	Peptidanaloge des menschlichen basischen myelinproteins
AU6020099A (en)	2000-03-14	Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE3585556D1 (de)	1992-04-16	Pharmazeutische zusammensetzungen, welche ein dipeptid enthalten.
ATE230797T1 (de)	2003-01-15	Stabile produkte des bakterientötenden/durchlässigkeiterhöhenden proteins (pbi) und diese enthaltende arzneimittelzusammensetzungen
ATE108662T1 (de)	1994-08-15	Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
DE3852636D1 (de)	1995-02-09	Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
IL109403A0 (en)	1994-07-31	Oral drug delivery compositions and methods
FI860153A0 (fi)	1986-01-13	Oligopeptider, deras mellanprodukter och foerfarande foer deras framstaellning.
WO1996028470A3 (en)	1996-11-14	Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
ATE377026T1 (de)	2007-11-15	Behandlung von fettleibigkeit
ATE60062T1 (de)	1991-02-15	Wachstumshormone freisetzende peptiden und methode fuer die behandlung von saeugetieren.
BG97123A (bg)	1993-12-24	Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
ATE3416T1 (de)	1983-06-15	Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
DE69430416D1 (de)	2002-05-23	Zusammensetzungen aus Aminosäure zur Behandlung von Infektionen
GR3001922T3 (en)	1992-11-23	Use of n,n'-bis-l-amino acid-l-cystin peptides in amino acid preparations for oral and parenteral administration
DE69102069D1 (de)	1994-06-23	5-aminosalicylsäurederivate zur therapie chronisch entzündlicher baucherkrankungen.
ATE92078T1 (de)	1993-08-15	Pharmakologisch aktive peptide.
DE3162674D1 (en)	1984-04-19	A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it
KR920700224A (ko)	1992-02-19	신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
ATE27822T1 (de)	1987-07-15	Hexapeptid, verfahren zur herstellung und pharmazeutische zusammensetzungen hieraus.
KR950704358A (ko)	1995-11-20	카텝신 l 특이적 저해 폴리펩티드